Zilia is reshaping preventive medicine through its flagship device, Zilia Ocular, a non-invasive retinal camera that combines advanced imaging, spectroscopy, and artificial intelligence to measure critical biomarkers like oxygen saturation directly in the eye. By analyzing the spectral fingerprint of reflected light, the system offers real-time metabolic and vascular insights—detecting early signs of diseases like glaucoma, diabetic retinopathy, macular degeneration, and more. With over 1,000 patients already enrolled in clinical studies and recent FDA clearance of its Zilia Ocular FC model, Zilia is moving swiftly from research into real-world clinical and drug‑development use. The technology leverages the unique status of the eye as a window into overall health, enabling earlier diagnosis and better patient outcomes through accessible, AI‑driven biomarker monitoring.